[1]李　芳　吴颖涛　马廉亭　卢文婕　杨　李.流式细胞术监测血小板活化指导颅内支架介入术后病人抗血小板治疗的价值[J].中国临床神经外科杂志,2020,(08):525-527.[doi:10.13798/j.issn.1009-153X.2020.08.009]
　LI Fang,WU Ying-tao,MA Lian-ting,et al.Value of platelet activation monitoring using flow cytometry to guide anti-platelet therapy in patients after intracranial stenting[J].,2020,(08):525-527.[doi:10.13798/j.issn.1009-153X.2020.08.009]
点击复制

流式细胞术监测血小板活化指导颅内支架介入术后病人抗血小板治疗的价值()
分享到：

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
期数:
2020年08期
页码:
525-527
栏目:
论著
出版日期:
2020-08-25

文章信息/Info

Title:
Value of platelet activation monitoring using flow cytometry to guide anti-platelet therapy in patients after intracranial stenting
文章编号:
1009-153X（2020）08-0525-03
作者:
李　芳　吴颖涛　马廉亭　卢文婕　杨　李
430070 武汉，中国人民解放军中部战区总医院检验科（李　芳、吴颖涛），神经外科（马廉亭）；430015 武汉，华中科技大学同济医学院附属武汉儿童医院血液肿瘤科（卢文婕、杨　李）
Author(s):
LI Fang1;  WU Ying-tao1;  MA Lian-ting2;  LU Wen-jie3;  YANG Li3.
1. Department of Clinical Laboratory, General Hospital of Central Theater Command, PLA, Wuhan 430070, China; 2. Department of Neurosurgery, General Hospital of Central Theater Command, PLA, Wuhan 430070, China; 3. Department of Hemotology and Oncology, W
关键词:
颅内支架介入术; 抗血小板治疗; 血小板活化; 流式细胞术
Keywords:
Intracranial stenting;  Antiplatelet therapy: Platelet activation;  Flow cytometry
分类号:
A
DOI:
10.13798/j.issn.1009-153X.2020.08.009
文献标志码:
R 743; R 815.2
摘要:
目的 探讨流式细胞术监测血小板活化指导颅内支架介入治疗术后病人抗血小板治疗的价值。方法 选择2013年1月至2016年4月支架介入治疗术后病人1 792例，采集空腹静脉血，用20 μmol/L ADP激活5 min，应用流式细胞仪监测CD62P阳性率，范围控制在20.0%~50.0%。所有病人随访1年。结果 1792例中，无不良事件1691例，出血96例，再梗死5例。无不良事件组ADP激活后CD62P阳性率[（42.34±19.35）%]显著低于再梗死组[（83.64±6.41）%；P<0.05]，但是明显高于出血组[（11.32±3.96）%；P<0.05]。ADP激活后CD62P阳性率<20.0%有247例，20.0%~50.0%有1195例，>50.0%有345例。<20.0%组出血发生率明显增高（P<0.05），>50.0%组再梗死发生率明显增高（P<0.05）。20.0%~50.0%组不良事件发生率最低（P<0.05）。结论 应用20 μmol/L的ADP激活血小板5 min，采用流式细胞仪监测CD62P阳性率，可精准指导颅内支架介入治疗术后病人抗血小板治疗，其安全有效范围为20.0%~50.0
Abstract:
Objective To explore the value of platelet activation monitoring (PAM) using flow cytometry (FCM) to guide the anti-platelet therapy in patients after intracranial stenting. Methods The fasting venous blood were collected from 1 792 patients who underwent intracranial stenting from January 2013 to April 2016. After activation using 20 μmol/L ADP for 5 minutes, the CD62P positive rate was detected by FCM, and the rate was controlled within 20.0%~50.0%. All the patients were followed up for 1 year. Results Of 1792 patients, 1691 had no adverse events, 96 had bleeding, and 5 had re-infarction. The positive rate of CD62P in the bleeding group [(11.32±3.96)%] was significantly lower than that [(42.34±19.35)%] in the no adverse event group (P<0.05), which was significantly lower than that [(83.64±6.41)%] in the re-infarction group (P<0.05). The positive rate of CD62P was <20.0% in 247 patients, 20.0%~50.0% in 1 195 patients, and >50.0% in 345 patients. The incidence of bleeding was significantly higher in the <20.0% group than those in 20.0%~50.0% and >50.0% groups (P<0.05). The incidence of re-infarction was significantly higher in the >50.0% group than those in <20% and 20%~50% groups (P<0.05). The incidence of adverse events was significantly lower in the 20.0%~50.0% group than those in >50% and <20% groups (P<0.05). Conclusions Using the FCM to monitor the positive rate of CD62P after activation for 5 minutes by 20umol/L ADP can accurately guide the anti-platelet therapy for patients after intracranial stenting, and the safe and effective range of the positive rate of CD62P is 20.0%~50.0

参考文献/References:

[1] Kozuma K. Antiplatelet therapy during perioperative period: double-edged sword [J]. J Cardiol, 2014, 64: 331-333.
[2] Michelson, Levin J. Platelets [M]. 2nd ed. San Diego： Else- vier/Academic Press, 2007. 545-563.
[3] van Velzen JF, Laros-van Gorkom BA, Pop GA. Multicolor flow cytometry for evaluation of platelet surface antigens and activation markers [J]. Thromb Res, 2012, 130: 92-98.
[4] Rubak P, Nissen PH, Kristensen SD. Investigation of plate- let function and platelet disorders using flow cytometry [J]. Platelets 2016, 27: 66-74.
[5] 候振江. 血液学检验[M]. 第3版，北京，人民卫生出版社， 2010. 247-248.
[6] 杨　李，卢文婕，蔡明俊，等. 血小板活化状态检测在颅内 动脉瘤支架置入术中的应用[J]. 中国临床神经外科杂 志，2013，18（9）：537-539.
[7] 马高亭，缪中荣. 抗血小板治疗在血管内治疗缺血性脑血 管病中的应用[J]. 中国卒中杂志，2020，15（2）：202-208.
[8] 陶贵周，王耀萱. 冠心病抗血小板治疗的进展[J]. 医学与 哲学（B），2018，39（12）：:26-27+77
[9] 张　灏，米登海. 抗血小板治疗[M]. 第1版. 北京：人民卫 生出版社，2011. 38-47.
[10] Sbrana S, Della Pina F, Rizza A, et al. Relationships between optical aggregometry (type born) and flow cytometry in evaluating ADP-induced platelet activation [J]. Cytome- try B Clin Cytom, 2008, 74(1): 30-39.
[11] Li-Na Qiu, Lin Wang, Xin Li, et al. Predictive value of high residual platelet reactivity by flow cytometry for outcomes of ischemic stroke patients on clopidogrel therapy [J]. J Stroke Cerebrovasc Dis, 2015, 24(6):1145-1152.
[12] Capodanno D, Ferreiro JL, Angiolillo DJ. Antiplatelet thera- py: new pharmacological agents and changing paradigms [J]. J Thromb Haemost, 2013, 11(1): 316-29.
[13] Michelson AD, Linden MD, Furman MI, et al. Evidence that preexistent variability in platelet response to ADP accounts for clopidogrel resistance [J]. J Thromb Haemost, 2007, 5 (1): 75-81.

相似文献/References:

[1]庄　严　邓引生　吴　旻　陈泽军　蒋　明　焦　磊.颅外段颈内动脉夹层的治疗[J].中国临床神经外科杂志,2015,(06):332.[doi:10.13798/j.issn.1009-153X.2015.06.004]
　ZHUANG Yan,DENG Yin-sheng,WU Min,et al.Treatment of extracranial internal carotid artery dissections (report of 4 cases)[J].,2015,(08):332.[doi:10.13798/j.issn.1009-153X.2015.06.004]
[2]李荔荣,任少华,郝旭东,等.替格瑞洛在氯吡格雷抵抗的颅内动脉瘤病人介入术后的应用[J].中国临床神经外科杂志,2022,27(05):390.[doi:10.13798/j.issn.1009-153X.2022.05.018]
[3]张一川 综述,柴尔青 审校.血栓弹力图在颅内动脉瘤支架辅助栓塞术后抗血小板治疗中的应用进展[J].中国临床神经外科杂志,2023,28(02):126.[doi:10.13798/j.issn.1009-153X.2023.02.022]

备注/Memo

备注/Memo:
（2018-05-11收稿，2020-05-22修回）通讯作者：杨　李，E-mail：yanglilifangbaby@163.com
更新日期/Last Update: 2020-08-18